Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Investment Securities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Gains from Investment Securities for 11 consecutive years, with $915213.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 83.3% to $915213.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $915213.0, a 83.3% decrease, with the full-year FY2024 number at $5.4 million, down 0.85% from a year prior.
  • Gains from Investment Securities was $915213.0 for Q3 2025 at Intellia Therapeutics, up from $692170.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $262.0 million in Q4 2021 to a low of -$3.0 million in Q4 2024.
  • A 5-year average of $19.8 million and a median of $800000.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 18166.67% in 2021, then plummeted 329.79% in 2024.
  • Intellia Therapeutics' Gains from Investment Securities stood at $262.0 million in 2021, then plummeted by 99.98% to $55144.0 in 2022, then skyrocketed by 2286.48% to $1.3 million in 2023, then tumbled by 329.79% to -$3.0 million in 2024, then skyrocketed by 130.26% to $915213.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Gains from Investment Securities are $915213.0 (Q3 2025), $692170.0 (Q2 2025), and $150340.0 (Q1 2025).